Articles tagged "B cells"

2018 American Transplant Congress
Increase on Regulatory Cells in Kidney Transplanted Patients Presenting Donor-Specific Antibodies
G. Maciel,¹ M. Fernandes,^1,2 E. Barbosa,² H. Rodrigues,¹ N. Panajotopolus,¹ F. Agena,² E. David-Neto,² V. Coelho,¹ M. Castro.²
¹Laboratory of Immunology, São Paulo University, São Paulo, Brazil; ²Renal Transplantation Service, Clinical Hospital, São Paulo, Brazil.
The role of anti-HLA donor specific antibodies (DSA) in increasing the risk of graft rejection is known. Nevertheless, not all patients with DSA develop rejection…
2018 American Transplant Congress
T Cell Exhaustion Contributes to Operational Tolerance of Liver Allografts in Pediatric Liver Transplant Recipients
B. Ramaswami,¹ M. Marrari,² O. Yoshida,⁵ X. Guo,³ W. Hoffman,³ C. Bentlejewski,² D. Metes,¹ A. Demetris,^1,2 A. Zeevi,² A. Thomson,¹ G. Mazariegos,⁴ G. Chalasani.^1,3
¹Surgery, Starzl Transplantation Institute, Pittsburgh, PA; ²Pathology, University of Pittsburgh, Pittsburgh, PA; ³Medicine, University of Pittsburgh, Pittsburgh, PA; ⁴Children's Hospital, University of Pittsburgh, Pittsburgh, PA; ⁵Gastroenterology, Ehime University Graduate School of Medicine, Toon-shi, Ehime-ken, Japan.
Operational tolerance in the absence of immunosuppression can be successfully attained in pediatric liver transplant recipients. Although DSA are observed in a proportion of operationally…
2018 American Transplant Congress
Achieving Allograft Tolerance through Antigen-Specific Regulatory B Cells
C. Rickert,^1,2 S. Kimura,^1,2 L. Kojima,¹ K. Lee,¹ M. Aburawi,¹ F. Fontan,¹ K. Deng,¹ H. Yeh,^1,2 J. Markmann.^1,2
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA; ²Transplantation Unit, Department of Surgery, Massachusetts General Hospital, Boston, MA.
IntroductionA complete understanding of the role of antigen-specificity in the development of B cell mediated allograft tolerance has remained elusive. Previous work in our lab…
2018 American Transplant Congress
Accommodation and Antibody Mediated Rejection Are Associated with Distinct TACI Polymorphisms in Kidney Transplant Recipients
M. Cascalho, M. Barbosa,¹ E. Farkash,² J. Platt.¹
¹Surgery, University of Michigan, Ann Arbor, MI; ²Pathology, University of Michigan, Ann Arbor, MI.
A. Trans-membrane Activator and CAML Interactor (TACI) gene is among the 5% most polymorphic genes in humans, TACI controls B cell differentiation and memory and…
2018 American Transplant Congress
Designing Novel Selective Immunoproteasome Inhibitors Reveals a Critical Role of the Immunoproteasome in Protecting Antibody Secreting B Cells from Apoptosis
J. Assaker,¹ N. Murakami,¹ S. Eskandari,¹ M. Uehara,¹ C. Nathan,² H. Li,³ G. Lin,² J. Azzi.¹
¹Transplantation Renal Center, Harvard Medical School, Boston; ²Microbiology and Immunology, Weill Cornell Medicine, New York; ³Cryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids.
Constitutive proteasomes (c-20S) are ubiquitously-expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Its inhibitor, bortezomib, is a plasma cell-targeted therapy used in…
2018 American Transplant Congress
Alloreactive B Cells Acquire Cell-Intrinsic Hyporesponsiveness in Tolerant Recipients
S. Khiew,¹ D. Jain,¹ J. Young,¹ J. Chen,¹ J. Yang,¹ Q. Wang,¹ D. Yin,¹ R. Sciammas,² A. Chong.¹
¹Department of Surgery, The University of Chicago, Chicago, IL; ²Comparative Medicine, University of California, Davis, CA.
Donor-specific transplantation tolerance has long been an aspiration of clinical transplantation. Recently, we have reported that multiple mechanisms are required to reinforce profound hyporesponsiveness of…
2018 American Transplant Congress
The Regulatory Role of Plasma Cells (as Bregs) is Counterbalanced by a NOVEL Inflammatory Role in Murine Transplant and Autoimmune Models
Z. Song,^1,2 Y. Zhou,² Q. Ding,¹ D. Rothstein.¹
¹Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh; ²School of Medicine, Tsinghua University, Beijing, China.
Plasma Cells (PCs; B220lowCD138hiBlimp1+Ig+) in LN and spleen were shown to be the major source of B cell lineage IL-10, and absence of PCs worsens…
2018 American Transplant Congress
Preemptive B Cell Depletion Modulates Pathogenic Alloimmunity Associated with Selective Non-Activating CD28 Blockade
N. O'Neill,¹ T. Zhang,¹ W. Sun,¹ G. Braileanu,¹ X. Cheng,¹ I. Tatarov,¹ W. Hassanein,¹ Z. Habibabady,¹ B. Cerel,¹ K. Reimann,² A. Azimzadeh,¹ R. Pierson.¹
¹Surgery, University of Maryland School of Medicine, Baltimore, MD; ²University of Massachusetts Medical School, Boston, MA.
Purpose: Because anti-donor alloantibody (alloAb) elaboration is associated with chronic allograft rejection, peri-transplant B cell depletion is being explored to modulate pathogenic alloimmunity. Here, we…
2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
J. Lee,¹ J. Park,² Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,³ J. Lee,⁴ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Internal Medicine (Gastroenterology), Yonsei University College of Medicine, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…
2018 American Transplant Congress
CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation
B. Nashan,¹ H. Tedesco,¹ M. van den Hoogen,¹ S. Berger,¹ D. Cibrik,¹ S. Mulgaonkar,¹ D. Leeser,¹ R. Alloway,¹ A. Patel,¹ J. Pratschke,¹ C. Sommerer,¹ A. Wiseman,¹ A. van Zuilen,¹ U. Laessing,² J. Rush,² B. Haraldsson,² O. Witzke.¹
¹CFZ533 Study Group, Basel, Switzerland; ²Novartis Pharma, Basel, Switzerland.
Purpose: To assess the potential of CFZ533 as primary immunosuppressant in a calcineurin(CNI)-free regimen in de novo kidney transplant (KTx) patients(pts).Method: CFZ533 is a new,…